Lineage Cell Therapeutics, Inc. (LCTX) Financials
LCTX Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| 2023-12-31 | 101.0 million | 39.0 million |
| 2023-09-30 | 106.2 million | 39.5 million |
| 2023-06-30 | 111.7 million | 40.4 million |
| 2023-03-31 | 113.2 million | 44.2 million |
LCTX Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| 2023-12-31 | -6.1 million | 1.1 million |
| 2023-09-30 | -5.2 million | 1.3 million |
| 2023-06-30 | -6.5 million | 1.3 million |
| 2023-03-31 | -11.4 million | 1.0 million |
LCTX Net Income
No data available :(
LCTX Cash and Debt
Graph available only for supporters. Become a supporter to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| 2023-12-31 | 35.5 million | - | 3.0 million |
| 2023-09-30 | 41.3 million | - | 3.1 million |
| 2023-06-30 | 45.9 million | - | 3.4 million |
| 2023-03-31 | 46.8 million | - | 3.6 million |
LCTX Shares Outstanding
LCTX Expenses
Graph available only for supporters. Become a supporter to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| 2023-12-31 | 91000 | 3.9 million | 4.3 million | 143001 |
| 2023-09-30 | 139000 | 3.7 million | 4.0 million | - |
| 2023-06-30 | 256000 | 3.9 million | 4.2 million | - |
| 2023-03-31 | 188000 | 4.2 million | 4.7 million | - |
LCTX Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| 2023-12-31 | 2.1 million | 431000 |
| 2023-09-30 | 1.2 million | 169000 |
| 2023-06-30 | 3.2 million | 127000 |
| 2023-03-31 | 2.4 million | 119000 |
LCTX
Price: $1.14
52 week price:
Earnings Per Share: -0.12 USD
P/E Ratio: -7.54
Exchange: ASE
Sector: Healthcare
Industry: Biotechnology
Volume: 400600
Market Capitalization: 245.1 million